Orchard Therapeutics PLC – (NASDAQ:ORTX) – Investment analysts at Wedbush issued their FY2023 earnings per share (EPS) estimates for Orchard Therapeutics in a research note issued on Friday, March 22nd. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.13) per share for the year. Wedbush has a “Outperform” rating and a $25.00 price target on the stock.

ORTX has been the topic of a number of other research reports. Cowen began coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an “outperform” rating and a $27.00 price objective on the stock. Goldman Sachs Group began coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They issued a “neutral” rating and a $18.00 price target on the stock. ValuEngine cut shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, JPMorgan Chase & Co. began coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They issued an “overweight” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $24.50.

ORTX stock opened at $16.85 on Monday. Orchard Therapeutics has a twelve month low of $8.65 and a twelve month high of $19.24. The firm has a market cap of $1.42 billion and a price-to-earnings ratio of -1.65.

Several hedge funds and other institutional investors have recently bought and sold shares of ORTX. Victory Capital Management Inc. bought a new position in shares of Orchard Therapeutics in the fourth quarter worth about $106,000. Northern Trust Corp purchased a new stake in Orchard Therapeutics in the fourth quarter worth about $579,000. Norges Bank purchased a new stake in Orchard Therapeutics in the fourth quarter worth about $629,000. Dean Capital Investments Management LLC purchased a new stake in Orchard Therapeutics in the fourth quarter worth about $674,000. Finally, Sofinnova Investments Inc. purchased a new stake in Orchard Therapeutics in the fourth quarter worth about $3,502,000. Hedge funds and other institutional investors own 57.82% of the company’s stock.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: Does the discount rate affect the economy?

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.